Opportunistic Pneumococcal Immunisation Trial in MALnutrition

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

February 28, 2029

Conditions
Severe Acute Malnutrition in ChildhoodPneumococcal DiseasePneumococcal VaccinesPneumococcal InfectionPneumonia in Children
Interventions
BIOLOGICAL

Pneumococcal conjugate vaccine

10-valent pneumococcal polysaccharide conjugate vaccine at a dosage of 2μg for each serotype polysaccharide for 1, 5, 6A, 7F, 9V, 14, 19A, 19F, 23F, and 4μg for serotype 6B, conjugated to a carrier protein (CRM197), polysorbate 20 and aluminium phosphate as an adjuvant. Administered as an intramuscular injection of 0.5mL.

BIOLOGICAL

Typhoid conjugate vaccine

Typhoid conjugate vaccine at a dosage of 25μg purified Vi capsular polysaccharide of Salmonella typhi Ty2 conjugated to Tetanus Toxoid with preservative (2-Phenoxyethanol). Administered as an intramuscular injection of 0.5mL.

Trial Locations (1)

Unknown

Guido Valadares National Hospital (HNGV), Dili

Sponsors
All Listed Sponsors
collaborator

Murdoch Childrens Research Institute

OTHER

collaborator

The University of Western Australia

OTHER

collaborator

University of Edinburgh

OTHER

collaborator

Timor-Leste Ministry of Health

UNKNOWN

lead

Nick Fancourt

OTHER